Skip to main content
Premium Trial:

Request an Annual Quote

Evotec, Indivumed Partner on Colorectal Cancer Drug Discovery

NEW YORK (GenomeWeb) — Evotec and Indivumed announced today that they have partnered to discover and develop new precision therapeutics for colorectal cancer.

Under the terms of the two-year alliance, the Hamburg, Germany-based companies will apply Evotec's PanHunter bioinformatics analysis platform and drug discovery technologies to a colorectal cancer cohort from Indivumed's IndivuType database, which integrates patients' clinical information with genomic, transcriptomic, proteomic, and digital histopathology data derived from biospecimens.

In exchange for access to the cohort, Evotec made an undisclosed payment to Indivumed. Both firms will contribute to data analysis, target identification and validation, and drug discovery efforts, but Evotec will be responsible for partnering and programs and platforms resulting from the collaboration.

Additional terms were not disclosed.

"The access to IndivuType will allow us to identify targets that are matched to CRC subpopulations [that] have been categorized due to molecular phenotypes and are thus expected to deliver more effective and durable drugs," Evotec CSO Cord Dohrmann said in a statement.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.